This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy of Prunus Domestica Extract in BPH

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02702947
Recruitment Status : Completed
First Posted : March 9, 2016
Last Update Posted : November 2, 2016
Sponsor:
Information provided by (Responsible Party):
Chemical Resources

Brief Summary:

Benign prostatic hyperplasia (BPH) is a nonmalignant enlargement of the prostate Prunus domestica bark contains three groups of active constituents: phytosterols (including beta-sitosterol), pentacyclic triterpenoids (including ursolic and oleaic acids) and ferulic esters of long-chain fatty alcohols (including ferulic esters of docosanol and tetracosanol).

The phytosterols, particularly beta-sitosterol, are found in numerous plants and are anti-inflammatory, inhibiting the synthesis of prostaglandins. Beta-sitosterol has been shown to be useful in cases of BPH by helping to reduce the normally elevated levels of prostaglandins in these patients.


Condition or disease Intervention/treatment Phase
BPH Dietary Supplement: Prunus domestica extract Phase 4

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 160 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: EFFICACY EVALUATION OF PRUNUS DOMESTICA EXTRACT ON BENIGN PROSTATE HYPERPLASIA (BPH): An Add on Study
Study Start Date : March 2014
Actual Primary Completion Date : May 2016
Actual Study Completion Date : September 2016

Arm Intervention/treatment
Experimental: Prunus Domestica
Prunus domestica extract capsules, 100mg, BD
Dietary Supplement: Prunus domestica extract
Prosman 1 capsule twice a day
Other Name: Prosman




Primary Outcome Measures :
  1. Reduction in prostate volume [ Time Frame: 12 weeks ]

Secondary Outcome Measures :
  1. Improvement in urinary flow parameters [ Time Frame: 12 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Age between 40 and 65 years
  • Only Male included
  • Has suffered from symptoms of BPH for at least the 6 months before Screening.
  • Has a prostate volume ≥ 20 mL and ≤ 70 mL as assessed by ultrasound
  • Has an IPSS ≥ 8 at Screening and Baseline
  • Patients willing to give informed consent in writing

Exclusion Criteria:

  • Neurogenic bladder dysfunction
  • Has bladder neck contracture or urethral stricture
  • Has acute or chronic prostatitis or urinary tract infection
  • Has a history of, prostate cancer or carcinoma of the prostate suspected on digital rectal exam.
  • Participation in any other clinical trial with in the last 30 days
  • Has resting systolic blood pressure (BP) > 160 mmHg or < 90 mmHg, or diastolic BP > 90 mmHg or < 60 mmHg at Screening.
  • Urine flow< 5mls/sec.
  • Use of any other herbal medications for treatment of BPH, associated symptoms and Erectile Dysfunction in past 1 month.
  • Has hematuria of unknown etiology.
  • Previous radiotherapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02702947


Locations
Layout table for location information
India
Department of Urology, King George's Medical University, Lucknow, UP, India
Lucknow, Uttar Pradesh, India, 226003
Sponsors and Collaborators
Chemical Resources
Investigators
Layout table for investigator information
Principal Investigator: Dr. Satyanarayan sankhwar, M.S., M.Ch. King George's Medical University, Lucknow, UP, India
Principal Investigator: Dr. Narsingh Verma, M.D. King George's Medical University, Lucknow, UP, India
Additional Information:
Publications:
Layout table for additonal information
Responsible Party: Chemical Resources
ClinicalTrials.gov Identifier: NCT02702947    
Other Study ID Numbers: CR/ BPH /11/13
First Posted: March 9, 2016    Key Record Dates
Last Update Posted: November 2, 2016
Last Verified: May 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Chemical Resources:
BPH
Prunus Domestica extract